Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.

ABSTRACT:

Purpose

We sought to define the prevalence and co-occurrence of actionable genomic alterations in patients with high-grade bladder cancer to serve as a platform for therapeutic drug discovery.

Patients and methods

An integrative analysis of 97 high-grade bladder tumors was conducted to identify actionable drug targets, which are defined as genomic alterations that have been clinically validated in another cancer type (eg, BRAF mutation) or alterations for which a selective inhibitor of the target or pathway is under clinical investigation. DNA copy number alterations (CNAs) were defined by using array comparative genomic hybridization. Mutation profiling was performed by using both mass spectroscopy-based genotyping and Sanger sequencing.

Results

Sixty-one percent of

SUBMITTER: Iyer G 

PROVIDER: S-EPMC3753703 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature